Guardant Health (GH) closed at $151.70 on November 13, 2026, down 2.0% from the previous close, on volume of 1,097,895 shares (30-day average 2,019,177).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 5, 2026 | Ratio Put Spread 1 by 4 | 20-Nov-26130[4x] : 175 P | 2,500 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 13-Nov 4:05 PM ET)
Guardant Health prices $500M convertible notes offering
Seeking Alpha News (Thu, 12-Nov 2:35 AM ET)
Guardant Health Prices $500 Million Convertible Senior Notes Offering
Business Wire (Thu, 12-Nov 1:09 AM ET)
Guardant Health plans $500M convertible note offering and related 2027 note repurchases
Seeking Alpha News (Wed, 11-Nov 4:31 PM ET)
Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032
Business Wire (Wed, 11-Nov 4:17 PM ET)
Business Wire (Wed, 11-Nov 8:46 AM ET)
Business Wire (Tue, 10-Nov 4:05 PM ET)
Guardant Health Earnings Call Signals Strong Growth Momentum
TipRanks (Mon, 9-Nov 7:15 PM ET)
Guardant Health to Participate in Upcoming Investor Conferences
Business Wire (Mon, 9-Nov 4:30 PM ET)
Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Business Wire (Thu, 5-Nov 4:05 PM ET)
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Guardant Health trades on the NASDAQ stock market under the symbol GH.
As of November 13, 2026, GH stock price declined to $151.70 with 1,097,895 million shares trading.
GH has a beta of 0.99, meaning it tends to be less sensitive to market movements. GH has a correlation of 0.05 to the broad based SPY ETF.
GH has a market cap of $20.36 billion. This is considered a Large Cap stock.
Last quarter Guardant Health reported $361 million in Revenue and -$.29 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.10.
In the last 3 years, GH traded as high as $191.05 and as low as $15.81.
The top ETF exchange traded funds that GH belongs to (by Net Assets): VTI, VB, VBK, VXF, ARKG.
GH has outperformed the market in the last year with a return of +61.2%, while the SPY ETF gained +13.4%. However, in the most recent history, GH shares have underperformed the stock market with its stock returning -4.9% in the last 3 month period and -15.2% for the last 2 week period, while SPY has returned -2.8% and -0.2%, respectively.
GH support price is $148.89 and resistance is $160.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GH shares will trade within this expected range on the day.
